Final answer:
The atypical antipsychotics clozapine and olanzapine are associated with the highest risk of metabolic syndrome compared to other pairs listed. They can lead to weight gain, dyslipidemia, and hyperglycemia.
Step-by-step explanation:
The risk of developing metabolic syndrome is higher with certain atypical antipsychotics. Metabolic syndrome is a cluster of conditions including increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels that can occur together, increasing your risk of heart disease, stroke, and diabetes.
Among the options listed, the pair of atypical antipsychotics associated with a higher risk of metabolic syndrome is clozapine and olanzapine. Both of these medications have been associated with weight gain, dyslipidemia, and hyperglycemia, which contribute to metabolic syndrome.
Risperidone and quetiapine, while still posing a risk, are generally considered to have a moderate risk compared to clozapine and olanzapine. Aripiprazole and ziprasidone are considered to have a lower risk of metabolic effects among the atypical antipsychotics.